| Pharmaceutical Information |
| Drug Name |
Testolactone |
| Drug ID |
BADD_D02169 |
| Description |
An antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer. |
| Indications and Usage |
For palliative treatment of advanced breast cancer in postmenopausal women. |
| Marketing Status |
approved; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB00894
|
| KEGG ID |
D00153
|
| MeSH ID |
D013738
|
| PubChem ID |
13769
|
| TTD Drug ID |
D0C7JF
|
| NDC Product Code |
Not Available |
| UNII |
6J9BLA949Q
|
| Synonyms |
Testolactone | 1-Dehydrotestolactone | 1 Dehydrotestolactone | delta(1)-Testolactone | Teslac |
|
| Chemical Information |
| Molecular Formula |
C19H24O3 |
| CAS Registry Number |
968-93-4 |
| SMILES |
CC12CCC3C(C1CCC(=O)O2)CCC4=CC(=O)C=CC34C |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
